The GSDMD Knockout PaTu 8988t Polyclonal Cells constitute a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from the PaTu 8988t human pancreatic ductal adenocarcinoma cell line, targeting gasdermin D (GSDMD). This heterogeneous knockout model enables functional studies of GSDMD-dependent pathways without clonal selection bias.
The PaTu 8988t cell line is an epithelial cell line derived from a liver metastasis of a primary pancreatic adenocarcinoma, making it a relevant model for metastatic pancreatic cancer research. Its aggressive growth characteristics and metastatic origin make it suitable for investigating molecular mechanisms of tumor progression, therapy resistance, and host?Ctumor inflammatory interactions.
GSDMD functions as the executioner of pyroptosis, a lytic programmed cell death pathway critical for host defense and inflammation. In response to pathogen- or damage-associated signals, pattern recognition receptors including NLRP3, AIM2, and NLRC4 assemble into inflammasomes, often engaging the adaptor ASC (PYCARD) to recruit and activate caspase-1. Additionally, cytosolic lipopolysaccharide can directly activate CASP4/5 in the non-canonical inflammasome. These active caspases proteolytically cleave GSDMD, releasing the autoinhibited N-terminal domain, which oligomerizes and inserts into the inner leaflet of the plasma membrane to form ~16-nm pores. Pore formation disrupts ionic gradients, causing cell swelling and eventual membrane rupture, accompanied by the rapid release of mature IL-1?? and IL-18 processed by the same caspases. Thus, GSDMD acts as a molecular switch converting inflammatory caspase activity into pyroptotic cell death and potent cytokine secretion.
In the context of pancreatic adenocarcinoma, pyroptosis exhibits context-dependent roles, potentially contributing to tumor suppression through inflammatory cell death or fostering a pro-tumorigenic microenvironment via chronic IL-1?? release. The GSDMD knockout in PaTu 8988t cells permits precise interrogation of these paradoxical functions. This system allows researchers to dissect the contribution of GSDMD to cell viability, cytokine production, and signaling crosstalk in response to chemotherapeutic agents, death receptor ligands, or bacterial products, thereby clarifying the role of pyroptosis in pancreatic cancer progression and treatment response.
These polyclonal knockout cells are applicable to a wide array of experimental approaches, including studies of pyroptosis in pancreatic cancer, inflammasome regulation, and inflammatory cell death mechanisms. Standard assays compatible with this model include western blotting for full-length and cleaved GSDMD, lactate dehydrogenase (LDH) release assays to quantify lytic death, enzyme-linked immunosorbent assays (ELISAs) for IL-1??, immunofluorescence microscopy to detect GSDMD pore formation, and flow cytometry for cell death and cytokine analysis. This versatile system supports both mechanistic studies and therapeutic screening campaigns aimed at modulating the GSDMD pathway. For further technical details, please contact Ascent Research.
